|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
FY2021
12 months to Jun 30, 2021
|
|
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Operating expenses: | ||||
| Research and development | ||||
| General and administrative | ||||
| Impairment loss on property, equipment and other long-lived assets | ||||
| Performance of contract liability to affiliate | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Equity in net losses of affiliate | ||||
| Foreign currency gain, net | ||||
| Fair value adjustment to VericiDx investment | ||||
| Fair value adjustment to convertible notes | ||||
| Other income, net | ||||
| Net loss before income taxes | ||||
| Income tax expense | ||||
| Net loss | ||||
| Net loss attributable to noncontrolling interest | ||||
| Net loss attributable to ordinary shareholders | ||||
| Net loss per ordinary share - basic | ||||
| Net loss per ordinary share - diluted | ||||
| Weighted average ordinary shares - basic | ||||
| Weighted average ordinary shares - diluted | ||||
| Other comprehensive income (loss): | ||||
| Changes in the fair value of the convertible notes | ||||
| Foreign exchange translation adjustment | ||||
| Comprehensive loss | ||||
| Comprehensive loss attributable to Renalytix | ||||
Loading...
